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Abstract 41 
Prime-boost vaccination strategies against HIV-1 often include multiple 42 
variants for a given immunogen for better coverage of the extensive 43 
viral diversity. To study the immunologic effects of this approach, we 44 
characterized breadth, phenotype, function and specificity of Gag-45 
specific T cells induced by a DNA-prime Modified Vaccinia Ankara 46 
(MVA)-boost vaccination strategy, which uses mismatched Gag 47 
immunogens in the TamoVac 01 phase IIa trial. Healthy Tanzanian 48 
volunteers received three injections of the DNA-SMI vaccine encoding 49 
for a subtype B and AB-recombinant Gagp37 and two vaccinations with 50 
MVA-CMDR encoding subtype A Gagp55. Gag-specific T-cell responses 51 
were studied in 42 vaccinees using fresh peripheral blood mononuclear 52 
cells. After the first MVA-CMDR boost, vaccine-induced IFN-+ Gag-53 
specific T cell responses were dominated by CD4+ T cells (compared to 54 
CD8+ T cells, p<0.001) that co-expressed IL-2 (66.4%) and/or 55 
TNF63.7.  A median of 3 antigenic regions were targeted with a 56 
higher median response magnitude to Gagp24 regions - more 57 
conserved between prime and boost - as compared to regions within 58 
Gagp15 (not primed) and Gagp17 (less conserved, both p<0.0001). Four 59 
regions within Gagp24 were each targeted by 45% to 74% of vaccinees 60 
upon restimulation with DNA-SMI-Gag matched peptides. The response 61 
rate to individual antigenic regions correlated with the sequence 62 
homology between the MVA and DNA Gag encoded immunogens 63 
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(p=0.04, r2=0.47). In summary, after the first MVA-CMDR boost, the 64 
sequence-mismatched DNA-prime MVA-boost vaccine strategy 65 
induced a Gag-specific T cell response that was dominated by 66 
polyfunctional CD4+ T cells and that targeted multiple antigenic 67 
regions within the conserved Gagp24 Protein. 68 
 69 
Importance 70 
Genetic diversity is a major challenge for the design of vaccines 71 
against variable viruses. While including multiple variants for a given 72 
immunogen in prime-boost vaccination strategies is one approach that 73 
aims to improve coverage for global virus variants, the immunologic 74 
consequences of this strategy have been poorly defined so far. It is 75 
unclear whether inclusion of multiple variants in prime-boost 76 
vaccination strategies improves recognition of variant viruses by T cells 77 
and by which mechanisms this would be achieved; either by improved 78 
cross-recogniton of multiple variants for a given antigenic region or 79 
rather through preferential targeting of antigenic regions more 80 
conserved between prime and boost. Engineering vaccines to induce 81 
adaptive immune responses that preferentially target conserved 82 
antigenic regions of viral vulnerability might facilitate better immune 83 
control after preventive and therapeutic vaccination for HIV and for 84 
other variable viruses. 85 
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Introduction 88 
High antigenic variability of common viruses causing either chronic 89 
(e.g. Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV)) or 90 
acute (e.g. Influenza Virus, Dengue Virus) disease complicates the 91 
design of efficacious vaccines. Vaccines against such variable viruses 92 
should optimally induce adaptive immune responses that target all 93 
variants of a vulnerable antigenic region to prevent infection or, if that 94 
cannot be achieved, at least facilitate immune control of viral 95 
replication to prevent disease progression. All virus proteomes, even 96 
the most variable ones, contain conserved regions, where functional 97 
constraints limit extensive sequence variability. Designing vaccines to 98 
focus immune recognition towards such conserved regions could be a 99 
viable strategy to improve vaccine efficacy against variable 100 
pathogens (1, 2). 101 
HIV is a good example of a highly variable virus. It causes persistent 102 
infection and rapidly escapes the HIV envelope (Env)-specific antibody 103 
response. Extensive sequence variability and glycosylation of the Env 104 
protein complicate Env based vaccine design (3, 4). In contrast, 105 
sequence variability within the group-specific antigen (Gag) is more 106 
limited due to functional constraints, but still differs between the capsid 107 
protein p24, the matrix protein p17 and proteins of the p15-encoding 108 
region (nucleocapsid and virion assembly proteins). An extensive body 109 
of evidence supports the concept that vaccine-induction of Gag-110 
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specific T-cell responses could be beneficial; Gag-specific T-cell 111 
responses are linked to viral control during chronic HIV infection (5-10). 112 
The breadth of Gag-recognition by CD8+ T-cells is associated with 113 
better viral control and slower disease progression (9, 10). Furthermore, 114 
the protective mechanism mediated by HLA class I alleles has been 115 
linked to CD8+ T-cell recognition of defined Gag regions (10, 11). 116 
Similarly, Gag-specific CD4+ T-cell responses appear to contribute to 117 
viral control, sharing similar features with the CD8+ T-cell response (12-118 
14). In rhesus monkeys, vaccine induced Gag-specific T-cell responses 119 
correlate with post-challenge immune control and prolonged survival 120 
after SIV challenge (15). Together, these data support the concept that 121 
induction of strong and broad Gag-specific T-cell responses targeting 122 
common sequence variants could potentially improve HIV vaccine 123 
efficacy against diverse HIV variants.  124 
The multi-subtype TaMoVac DNA/MVA regimen used in the TaMoVac 125 
01 phase IIa trial induced strong Gag-specific T-cell responses (16, 17). 126 
This offered the opportunity to address the hypothesis that delivery of 127 
non-identical, but related immunogens preferentially induces T cell 128 
responses to antigenic regions more conserved between the 129 
immunogens. We found that the sequence mismatched TaMoVac01 130 
DNA-MVA vaccination induced broad recognition of conserved 131 
antigenic regions within Gagp24. 132 
133 
 o
n
 July 25, 2017 by UC London Library Services
http://jvi.asm.org/
D
ow
nloaded from
 
8 
 
Results 134 
Relative conservation of Gag p24 in a mixed subtype epidemic 135 
In order to define the degree of conservation within Mbeyan HIV Gag 136 
sequences, we analyzed previously published sequences and 137 
determined the distribution of subtypes and recombinant forms (RF). 138 
Pure subtype C sequences were found most frequently (57.1%) 139 
followed by unique subtype A-containing Recombinant Forms (RFs) 140 
(20.9%), pure subtype A Gag sequences (19.8%) and CD RFs (2.2%, 141 
Figure 1). In order to estimate the variability at each Gag amino acid 142 
position, the Shannon entropy score, was then calculated (Fig. 1b). 143 
Gag p24 showed the highest conservation with 82.6% of aa positions 144 
with an entropy score below 0.5 compared to the less conserved p17 145 
(55.7%) and the least conserved p15 (44.8%). Similarly, the median 146 
Shannon entropy score was lowest for p24 (0.14), followed by p17 (0.37) 147 
and p15 (0.49). 148 
 149 
Preferential induction of T-cells targeting Gagp24 protein by sequence 150 
mismatched DNA/MVA vaccination 151 
The DNA vaccine included two plasmids encoding for SMI-Gagp37 with 152 
an identical p17 subtype B sequence linked to subtype B or subtype A 153 
p24 sequences (Figure 2). The MVA-CMDR-Gagp55 boost encoded for a 154 
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subtype A Gagp55 and included the p15 region. Within the p17 region, 155 
21.2% (28 of 132) of aa positions were mismatched between the DNA-156 
SMI prime and MVA-CMDR boost. The Gagp24 subtype A and subtype B 157 
sequences included in the DNA-SMI prime differed from the MVA-158 
CMDR boost in 7.8% (18 mismatches in 231) and 11.7% (27 mismatches 159 
in 231) of aa positions, respectively. The p15 region represented a 100% 160 
mismatch to the DNA-SMI prime.  161 
 162 
IFN-+ Gag-specific T cell responses were not detected during the pre-163 
vaccination visit upon MVA-CMDR-Gagp55 restimulation, but were 164 
present in 15% of vaccinees upon DNA-SMI-Gagp37 restimulation (range 165 
60-165 SFC/106 PBMC, data not shown). Gag-specific T cell numbers 166 
already peaked after the first MVA-CMDR boost with a median of 228 167 
SFC/106 PBMC and significantly lower numbers of Gag-specific T cells 168 
after the second boost (p<0.05 for both peptide pools). Magnitude of T 169 
cell responses against the control peptide pools CEF (median 83 and 170 
90 SFC/106 PBMC, p=0.58) and CMVpp65 (median 1243 and 938 171 
SFC/106 PBMC, p=0.2) were comparable for both visits.  172 
Because vaccine-induced IFN-+ Gag-specific T cell responses peaked 173 
after the first MVA-CMDR boost, we focus on this time point in the 174 
subsequnt analyses. ICS data from 41 vaccine recipients were eligible 175 
for further analyses. IFN-+ Gag-specific CD4 and CD8+ T cell responses 176 
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were detected in 30 and 14 of 41 subjects, respectively after 177 
restimulation with the MVA-CMDR-Gagp55 peptide pool (Fisher`s Exact 178 
test; p=0.0008). Likewise, significantly higher frequencies of CD4
+ as 179 
compared to CD8+ IFN-+ Gag-specific T cells were detected after re-180 
stimulation with either the MVA-CMDR-Gagp55 (median; 0.04% versus 181 
0.01%; p<0.0001, figure 3A) or the DNA-SMI-Gagp37 (median; 0.06% v 182 
0.01% p=0.0002) peptide pool after the first MVA-CMDR boost. IFN-+ 183 
Gag-specific CD4 T cells frequently co-expressed IL-2 (66.4%, mean of 184 
both Gag peptide pools) or TNF- (63.7%) with 49.9% co-expressing IL-2 185 
and TNF- and high concordance between the two tested Gag 186 
peptide pools (Figure 3B). The CCR5-ligand Mip-1 and degranulation 187 
marker CD107 were co-expressed by only 20% (CMDR-Gagp55: 13%) 188 
and 11% (CMDR-Gagp55: 7%) of IFN-+ Gag-specific CD4
+ T cells, 189 
respectively. By contrast high frequencies of IFN-+ CD4+ T cells co-190 
expressed Mip-1 (59%) and/or CD107 (53%) after re-stimulation with 191 
CMVpp65 peptides, including a significant proportion (16%) of 192 
polyfunctional cells expressing all assessed functional markers, which is 193 
concordant with previous reports (18). Almost 75% of IFN-+ Gag-194 
specific CD8 T cells co-expressed Mip-1 and almost 50% were CD107+ 195 
indicating degranulation of cytotoxic granula. 196 
 197 
Breadth and specificity of Gag-specific T cell recognition were 198 
determined in 42 vaccine recipients using the IFN--ELISPOT on freshly 199 
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isolated PBMCs, after re-stimulation with linear consecutive peptide 200 
pools matching for MVA-CMDR-Gagp55 (n=9 pools) and DNA-SMI-201 
Gagp37 (n=7 pools). Median breadth of Gag recognition was 3 peptide 202 
pools (range 0 - 8, Fig. 3c). The majority of the 42 vaccine recipients 203 
responded to at least one DNA-SMI-Gagp37 (n=36, 85.7%) or MVA-204 
CMDR-Gagp55 peptide pool (n=33, 78.6%).  In order to compare 205 
magnitude of T cell responses against the different Gag regions and 206 
account for sequence lengths of p17, p24, and p15, we calculated 207 
average SFC values as per 15_mer peptide for each Gag region.  208 
Antigenic regions within p24 were recognized at a higher median 209 
magnitude (14.55 SFC/106 PBMC/15mer_peptide) compared to those 210 
in the more variable p17 and p15 regions (both 6.52 SFC/106 211 
PBMC/15mer_peptide, p<0.0001, Fig. 4a). The magnitude of response 212 
to p17 (median of 6.52 SFC/106 PBMC/15mer_peptide for MVA-CMDR 213 
and 6.0 SFC/106 PBMC/15mer_peptide for DNA-SMI) was similar to the 214 
response to p15 (p=0.95).  215 
Ten of the 42 vaccine recipients (23.8%) mounted SMI Gagp17 specific T-216 
cell responses and 36 volunteers (85.7%) responded to SMI-Gagp24. 217 
Eight vaccine recipients (19.0%) responded to CMDR-Gagp17, 32 218 
(76.2%) to CMDR-Gagp24, and 8 (19.0%) to CMDR-Gagp15. Recognition 219 
of individual antigenic regions within Gagp24 was comparable between 220 
DNA and MVA encoded variants (Fig. 4b). Pools 5 (HxB aa 225-290) 221 
and 6 (aa 275-347) were immunodominant with 57.1% (CMDR-Gag 222 
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peptides: 47.6%) and 73.8% (CMDR-Gag peptides: 57.1%) responders 223 
after restimulation with the SMI Gag peptides, respectively. Pool 5 was 224 
targeted with a median magnitude of 38.65 SFC/106 PBMCs/15mer (SMI 225 
Gag peptides) and 35.19 SFC/106 PBMCs/15mer (CMDR-Gag 226 
peptides), respectively. Pool 6 was targeted with a median magnitude 227 
27.74 SFC/106 PBMCs/15mer (SMI-Gag peptides) and 29.79 SFC/106 228 
PBMCs/15mer (CMDR-Gag peptides).  229 
Next we mapped individual MVA-CMDR-Gagp55 peptide responses 230 
(Figure 4c) in 39 vaccine recipients using cryopreserved PBMC. Results 231 
from 3 vaccine recipients were excluded because of invalid ELISpot 232 
results. Positive peptide-specific ELISpot responses were detected in 23 233 
of 39 (60%) vaccine recipients. The 23 responders almost exclusively 234 
recognized peptides located within the p24 region. Four individual 235 
peptide responses were detected in p17 and two within p15. When 236 
counting responses to consecutive peptides as a single antigenic 237 
region, these 23 responders recognized a mean of 4 antigenic regions - 238 
ranging from one (26% of subjects (6/23)) to 12 antigenic regions 239 
recognized (4.3% (1/23)). The peptide YVDRFYKTLRAEQAT (pool 6, HxB 240 
position aa 296-310) was the most frequently recognized with 39.13% (9 241 
of 23) responders, followed by the peptide YKRWIILGLNKIVRMY (pool 5, 242 
aa 262-277, 30.43% responders). Four peptides within p24 were 243 
recognized with an equal frequency of 26.09%,; GATPQDLNMMLNIVGG 244 
(pool 4, aa 178-193), IAGTTSTLQEQIGWMT (pool 5, aa 236-251), 245 
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ILGLNKIVRMYSPVSI(9) (pool 5, aa 267-282) and WMTETLLVQNANPDCK 246 
(pool 6, aa 316-331). As shown in Figure 4d, the six most frequently 247 
recognized antigenic regions had only 0 or 1 aa difference between 248 
the SMI-DNA-prime encoded Gagp37 sequences (DNA B or BA) and the 249 
MVA-CMDR boost encoded Gagp55 sequences. These data indicate 250 
that hotspots of the vaccine-induced Gag recognition by T cells were 251 
exlusively located within p24, whereas recognition of antigenic regions 252 
within p17 and p15 appeared attenuated.  253 
 254 
We next compared the frequency of responders to a given antigenic 255 
region with the region-specific amino acid mismatches between the 256 
DNA- and the MVA-encoded Gag sequences using linear regression 257 
analysis (Figure 5). Plotting the frequency of responders against the 258 
sequence heterogeneity between the encoded aa sequence of the 259 
DNA-SMI-Gagp37 prime and the MVA-CMDR-Gagp55 boost for each 260 
linear peptide pool, we found a linear correlation between region-261 
specific aa mismatches and the frequency of responders to a given 262 
antigenic region (r2=0.69, p=0.04 (DNA-SMI-Gagp37), Figure 5a) and 263 
r2=0.45, p=0.07 (MVA-CMDR-Gagp55), suggesting that higher levels of 264 
sequence conservation between DNA-SMI-Gagp37 prime and MVA-265 
CMDR-Gagp55 boost contribute to higher frequencies of recognition 266 
within more conserved Gag regions. 267 
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The link between the level of sequence conservation within a given 268 
antigenic region and its recognition could further be substantiated by 269 
linear regression analysis. The number of aa mismatches between 270 
priming DNA Gagp24 encoded subtype B sequence and boosting Gag 271 
aa sequences (MVA) correlated with the frequency of responders 272 
(Figure 5b, r2=0.01 and p=0.0332) and the magnitude of response 273 
(Figure 5c, p=0.04, r2=0.04) to a given Gagp24 peptide. These data 274 
support the concept that the sequence heterologous prime-boost 275 
vaccination strategy applied during TaMoVac 01 contributed to 276 
preferential recognition of the more conserved antigenic regions within 277 
Gag. 278 
 279 
 280 
281 
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Discussion 282 
Genetic diversity poses a major challenge to the design of efficacious 283 
vaccines against HIV-1 and other variable viruses. Several vaccination 284 
strategies have been tested to address this extensive diversity of HIV-1 285 
(2). The TaMoVac 01 study incorporated multiple variants of the same 286 
immunogen in the vaccine formulation (16, 17, 19). The immunologic 287 
consequences of such vaccination strategies incorporating multiple 288 
variants and in particular the impact on the pattern of antigen 289 
recognition - have only been poorly defined so far. Inclusion of three 290 
immunogen variants elicited strong Gag-specific T-cell responses in the 291 
TaMoVac 01 and HIVIS studies (16, 17) providing the opportunity to 292 
study parameters that potentially influence the immunodominance 293 
pattern of vaccine-induced Gag recognition by T cells. The analysis of 294 
91 Gag sequences confirmed previous reports that the capsid antigen 295 
p24 shows the highest degree of conservation followed by the less 296 
conserved p17 and p15 (20).  297 
 298 
In TaMoVac 01 vaccinees, antigenic regions within conserved Gagp24 299 
regions were preferentially targeted after the first MVA-CMDR boost. A 300 
comparative analysis of HIV-1 rAd-5 T-cell based vaccine clinical trials 301 
Merck16, HVTN 054 and HVTN 502/Step, which included closely related 302 
Gag immunogen sequences and did not include DNA priming, found 303 
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considerable variation in the recognition of Gag regions (21). HVTN 054 304 
showed an accumulation of hotspots within Gagp24, whereas hotspots 305 
of T cell recognition were more evenly distributed within Gag for 306 
Merck16 and HVTN 502/Step. In comparison, the sequence 307 
mismatched DNA/MVA TaMoVac vaccine “focused” T-cell responses 308 
even more on highly conserved Gagp24 regions. The strength of 309 
induced T cell responses against individual antigenic regions in Gagp24 310 
correlated with the degree of conservation between the SMI-DNA 311 
encoded subtype B and MVA-CMDR encoded subtype A sequence 312 
variants. While no such correlation was detected for the DNA encoded 313 
subtype A variant, the six most frequently targeted peptides showed 314 
only none or one aa mismatch when taking both DNA encoded 315 
Gagp24 variants into account. Hence, immune recognition of peptides 316 
with high degree of variability between MVA-CMDR and DNA-Gagp37.1 317 
(subtype A, Figure 2) were probably primed by the other DNA- Gagp37 318 
variant (subtype B). 319 
What is the mechanism underlying this preferential targeting of more 320 
conserved antigenic regions within Gagp24 in TaMoVac01 vaccinees? 321 
One possibility is that induction of T-cell responses towards more 322 
variable epitopes - more common in Gagp17 and Gagp15 - was 323 
negatively affected by increasing numbers of mismatched amino acid 324 
positions within a given epitope. Immunodominat Gag-specific CD8+ T-325 
cell populations targeting the epitope variants TL9M7 (TPQDLNMML) 326 
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and TL9T7 (TPQDLNTML) during natural HIV subtype A and subtype C 327 
infections are completely different in their clonotypic composition(22). 328 
It is therefore plausible that certain T-cell clonotypes induced by one 329 
immunogen sequence cannot be boosted by certain other sequence 330 
variants or that boosting is suboptimal; however, if T-cell clonotypes 331 
partially overlap in their recognition of the two epitope variants, these 332 
cross-reactive clonotypes would be boosted stronger, resulting in 333 
improved variant cross-recognition and "focusing" towards such cross-334 
reactive clonotypes. Our data show that recognition of epitopes with 335 
more than 2 mismatches is completely abrogated (Figure 5 C, D).  A 336 
high number of epitope variant mismatches is therefore likely to abolish 337 
any efficient boosting. Of note, based on our analyses of 91 Mbeyan 338 
sequences, the tested CMDR-Gag sequence variants for the peptides 339 
P1 to P6 always closely matched the most frequent Mbeyan variants 340 
with ≤2 amino acid substitutions. In summary a variety of mechanisms 341 
probably contributed to preferential T cell recognition of more 342 
conserved Gag regions in the TaMoVac01 study using mismatched 343 
immunogen sequences. 344 
 345 
All immunodominant regions recognized by the TaMoVac 01 346 
vaccinees have also been identified in previous studies. P1 347 
(YVDRFYKTLRAEQAT) is an immunodominant target for CD4+ and CD8+ 348 
T-cells during early and chronic infection (14, 23, 24) and was also a 349 
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hotspot in the HVTN502/Step and HVTN 054 trials (21). P2 350 
(YKRWIILGLNKIVRMY) is frequently targeted by CD4+ T cells during early 351 
and chronic HIV infection (14) and was a hotspot in the Step trial 352 
(21)(39). P3 (GATPQDLNMMLNIVGG) contains the highly 353 
immunodominant B42/B81 restricted TL9 epitope (22, 24-26). P4 to P6 354 
also contained previously described epitopes (14, 23). Inherent 355 
immunogenicity of these peptide sequences P1-P6 could also 356 
contribute to their preferential recognition as these were also 357 
frequently recognized by T cells in natural infection or in other trials.  358 
 359 
Most of individual peptide-specific T cell responses after the first MVA-360 
CMDR boost were most likely mediated by CD4+ compared to CD8+ T 361 
cells, even though we were not able to phenotype individual vaccine-362 
induced peptide-specific T-cell responses from cryopreserved PBMC. 363 
After the second MVA-CMDR boost, 73% (32 of 44) of vaccinees had 364 
higher frequencies of Gag-specific IFN-+ CD8+ T-cell as compared to 365 
after the first MVA boost, suggesting that optimal induction of Gag-366 
specific CD8 T cell responses probably need a second MVA boost.  367 
One limitation of this study is that cryopreservation negatively affected 368 
our ability to detect vaccine-induced T cell responses. We did not 369 
observe this phenomenon during previous studies for natural HIV- or 370 
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MTB-specific T-cell responses(22, 27). However, this phenomenon is not 371 
unknown (28).  372 
 373 
In conclusion, our results show that after one MVA-CMDR boost the 374 
sequence mismatched TaMoVac 01 DNA prime/MVA boost vaccine 375 
regimen induced Gag specific T-cell responses that were dominated 376 
by CD4+ T cells co-expressing IL-2 and TNF- and targeted multiple 377 
conserved antigenic regions within Gagp24.  378 
379 
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 Methods 380 
Study Design and samples 381 
The TaMoVac 01 phase 2a trial was described in detail, previously (16). 382 
Briefly, this randomized controlled trial was performed at Muhimbili 383 
University of Health and Allied Science (MUHAS) and the National 384 
Institute for Medical Research -Mbeya Medical Research Center (NIMR-385 
MMRC) in Mbeya, Tanzania with a total of 120 healthy, HIV-negative 386 
individuals, aged 18-40 years. Immunosuppressive medications were 387 
exclusion criteria. The TaMoVac 01 trial participants received two or 388 
five intradermal (ID) injections of DNA/Placebo at weeks 0, 4 and 12 389 
and were boosted with two MVA-CMDR/Placebo intramuscular (IM) 390 
injections at weeks 30 and 46. The DNA/Placebo was administered 391 
intradermally in the skin over both deltoids by using a Biojector 2000® 392 
needleless device (Bioject Medical Technologies, Inc., Tualatin, OR, 393 
USA), the MVA injections were administered into the left deltoid muscle. 394 
The DNA-SMI vaccine (Vecura, Huddinge, Stockholm Sweden) was 395 
composed of 7 plasmids encoding the HIV-1 genes Env (subtype A, B 396 
and C respectively), Rev clade B, Gag (subtype A and A/B) and 397 
reverse transcriptase subtype B (for details see (29)) and was 398 
administered at either 600µg or 1000µg total. The recombinant 399 
modified vaccinia virus Ankara (MVA) expressing HIV-1 gp150 clade E 400 
as well as gag and pol clade A (MVA-CMDR) was manufactured by 401 
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Walter Reed Army Institute of Research (WRAIR) (30) and administered 402 
at 108 pfu. 403 
 404 
The study was reviewed and approved by the National Ethics 405 
Committee, the Institutional Review Board (IRB) at the NIMR-MMRC and 406 
the MUHAS IRB in compliance with national guidelines and institutional 407 
policies (Clinical Trials Registration: ATM2010050002122368), and 408 
informed consent was obtained in accordance with the Declaration of 409 
Helsinki.  410 
In the present study, samples collected at two weeks after the first 411 
MVA-CMDR vaccination - when vaccine-induced T cell responses 412 
peaked - from 42 vaccine recipients at the National Institute for 413 
Medical Research – Mbeya Medical Research Center and who did not 414 
become HIV infected during the trial were used for analyses. 415 
 416 
HIV genetic sequence analyses 417 
HIV-1 Gag sequences included in the phylogenetic analyses were from 418 
91 HIV-positive subjects from the Mbeya region and have the 419 
Genebank accession numbers FJ853501 to FJ85359 (22). The subtypes 420 
and recombinant forms were determined using the jpHMM-HIV tool 421 
(http://jphmm.gobics.de/submission_hiv). 422 
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 423 
Peptide antigen and peptide pool design 424 
DNA-SMI-Gagp37 and MVA-CMDR-Gagp55 peptide sets consisted of 15- 425 
to 18-mer peptides overlapping by 11 amino acids had a purity of 426 
>80% (JPT peptide technologies, Berlin). Individual peptide variants of 427 
identical length for a given Gag region were used to allow for direct 428 
comparison of T-cell responses targeting MVA or DNA-encoded 429 
peptide variants and to prevent artifacts with linked to intrapeptide 430 
epitope location (24, 31). Peptide maxipools including all peptides for 431 
the DNA-SMI-Gagp37 and MVA-CMDR-Gagp55 immunogens were used 432 
to study phenotypic and functional characteristics of vaccine-induced 433 
Gag-specific T cell responses; Linear peptide pools were used to test T-434 
cell responses against distinct antigenic regions (Figure 2); nine pools 435 
for MVA-CMDR-Gagp55 and 7 pools for DNA-SMI-Gagp37..  436 
 437 
Intracellular cytokine staining (ICS) 438 
A 8-colour ICS assay was performed on fresh PBMC were stimulated in 439 
the presence of Brefeldin A (5(g/ml Sigma-Aldrich) for 6 hours with 440 
either MVA-CMDR-Gagp55 or DNA-SMI-Gagp37 maxipools 441 
(1(g/ml/peptide), nothing (negative control) or the control antigens 442 
(CMVpp65 peptide pool (0.5(g/ml/peptide) and Staphylococcus 443 
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enterococcus Toxin B (1(g/ml, Sigma-Aldrich). Stimulated PBMCs were 444 
then stained with α-CD3 APC-Cy7 (BD Biosciences Europe, 445 
Erembodegem, Belgium), α-CD4 PerCp-Cy5.5 (ebioscience, San Diego, 446 
CA), α-CD8 V500 (BD Bioscience), α–TNF-α Pe-Cy7 (BD), α-IFN-γ V450 447 
(BD), α-IL-2 APC (BD), α-MIP-1β PE (BD), α-CD107 FITC (ebioscience). 448 
Acquisition of samples was performed using a FACSCanto II flow 449 
cytometer with acquisition-defined compensation using BD 450 
CompBeads (BD). Flow Cytometry results were analysed using FlowJo 451 
software, version 9.6.4 (Tree Star, Ashland, OR) and SPICE, version 5.35, 452 
downloaded from http://exon.niaid.nih.gov (32). A minimum of 50.000 453 
CD3+ lymphocytes were required for a sample to be included in the 454 
analysis. Background reactivity, defined by using unstimulated 455 
negative controls, was subtracted for analyses of antigen-specific T cell 456 
responses. IFN-+ T cell frequencies >0.025% were considered a positive 457 
response. 458 
 459 
IFNγ ELISPOT assay 460 
The IFN-γ ELISPOTPLUS kit (Mabtech, Nacka, Sweden) was used 461 
according to the instructions of the manufacturer. Fresh Peripheral 462 
Blood Mononuclear Cells (PBMC) were stimulated with linear peptide 463 
pools matching DNA-SMI-Gagp37 and MVA-CMDR-Gagp55 (described 464 
below, JPT, Berlin, Germany) (Figure 2). Frequencies of antigen-specific 465 
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spot-forming cells (SFC) were measured with an automated ELISPOT 466 
reader (Immunospot, C.T.L., Bonn, Germany). Responses were 467 
considered positive when the number of Spot Forming Cells (SFC) was 468 
at least four times the medium control and >55 SFC/106 PBMCs (33). 469 
Mapping of individual peptide responses was performed based on the 470 
peptide pool matrix ELISPOT results and testing cryopreserved PBMC. 471 
Responses of stimulated PBMCs with a SFC count higher than 2-fold the 472 
unstimulated medium control and ≥50 SCF/106 PBMCs cells were 473 
considered positive. Samples with a medium control of >60 SFC/PBMCs 474 
were excluded from analyses.  475 
 476 
Statistical analyses 477 
Statistical analyses were performed using Prism version 6.0 (GraphPad, 478 
Inc). Comparisons of two groups were performed with the Mann-479 
Whitney test. Magnitudes of CD4 and CD8 T cell responses were 480 
performed with the Wilcoxon signed-rank test. Number of responders 481 
with IFN-+ CD4 and CD8 T cell responses were compared using The 482 
Fisher`s Exact test. The linear relationship between the number of 483 
mismatched amino acid positions within a given antigenic region and 484 
the corresponding frequency of recognition and response magnitude 485 
was calculated using linear regression analyses. Tests used for statistical 486 
analysis are mentioned in the figure legends.487 
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Figure legends 632 
Figure 1. Diversity of HIV-1 Gag protein sequences originating from the 633 
Mbeya Region. 634 
The distribution of subtypes and unique recombinant forms of Gag 635 
polyprotein sequences from 91 HIV infected subjects from the Mbeya 636 
Region is shown in the pie chart (A). A Shannon Entropy Plot generated 637 
from these Gag sequences is shown in (B). 638 
 639 
Figure 2. Immunogen sequences included in the DNA-Gag prime and 640 
Modified Vaccinia Ankara (MVA)-Gag bost and their coverage by 641 
peptide pools 642 
The seven DNA peptide pools covered the Gagp37 region consisting of 643 
p17 (blue) and p24 (grey), whereas the nine MVA-Gag peptide pools 644 
covered the Gagp55 precursor protein including the p15 region (red) in 645 
addition to p17 and p24. The p15 region was only covered by MVA-646 
Gag peptide pools 8 and 9. 647 
 648 
Figure 3. Phenotype, function and breadth of vaccine-induced Gag-649 
specific T cell responses 650 
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Representative Dot Plots for the analyses of Gag-specific CD4 and CD8 651 
T cell functions are shown in (A). Frequency of IFN-+ CD4+ and CD8+ T 652 
cell after stimulation of freshly isolated PBMC with whole MVA-CMDR-653 
Gagp55 (left panel) or DNA-SMI-Gagp37 peptide pools (right panel) in 41 654 
vaccinees are shown in (B). Co-expression of additional functions 655 
(TNF, Mip-1, IL2 and the degranulation marker CD107) is shown in (C) 656 
for IFN+CD4 (left) and IFN+CD8+ (right) T cells. The four colour coded 657 
arcs indicate the proportion of cells co-expressing the four additional 658 
functions. The colour-coded pies symbolize the 16 possible functional 659 
combinations. Intracellular cytokine staining was performed using fresh 660 
PBMC stimulated overnight with the indicated antigens as well as the 661 
control antigens Staphylococcus enterotoxin B and CMVpp65. The 662 
number of different antigenic regions (linear peptide pools, x-axis) 663 
recognized by TaMoVac vaccinees (n=42) is shown in (D) and was 664 
determined using the IFN- ELISpot. The frequency of subjects with a 665 
given Gag response breadth is indicated on the y-axis. Nine and 7 666 
linear peptide pools matching MVA-CMDR-Gagp55 (gray bars) or DNA-667 
SMI-Gagp37 (black bars) subdivided Gag into distinct antigenic regions, 668 
respectively. Statistical comparison in (B) was performed using 669 
Wilcoxon-matched pairs-signed rank-test.  670 
 671 
Figure 4. Recognition of Gag antigenic regions by vaccine induced T-672 
cells 673 
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A comparison of the magnitude of Gag-specific T-cell responses (Y-674 
axis) targeting antigenic regions within p17, p24 and p15 normalized as 675 
per 15mer peptide is shown in (A). The frequency of responders is 676 
shown for different Gag regions (B). Vaccine-induced T-cell responses 677 
were characterized using IFN-( ELISpot in 42 participants after 678 
stimulation of fresh PBMCs with 9 and 7 peptide pools matching MVA-679 
CMDR-Gagp55 (grey bars) and DNA-Gagp37 (black bars), respectively. 680 
The frequency of responders for individual MVA-CMDR-Gagp55 681 
matched peptides is shown in (C) and is based on 23 subjects with at 682 
least 1 detectable response against on individual peptide during fine 683 
mapping using cryopreserved instead of fresh PBMC. The key data for 684 
the most frequently recognized peptides are shown in (D). Cut off for a 685 
positive response was 2-fold the unstimulated control. Corresponding 686 
Gag regions p15, p17 and p24 are indicated in (B) and (C). 687 
 688 
Figure 5. Linear regression analyses between DNA-SMI-Gagp37 and 689 
MVA-CMDR-Gagp55 sequence mismatches and induced T-cell 690 
responses targeting specific antigenic regions. 691 
A linear regression analyses was performed to study the association of 692 
immunogen-encoded amino acid mismatches and the respective T 693 
cell response rate to the DNA-SMI-Gagp37 pools 1 to 6 (A). T cell 694 
responses were detected using the IFN- ELISPOT and freshly isolated 695 
 o
n
 July 25, 2017 by UC London Library Services
http://jvi.asm.org/
D
ow
nloaded from
 
32 
 
PBMC Pool 7 was excluded because it only contains 3 instead of 11 696 
peptides. A comparison of mismatches between MVA-CMDR-Gagp55 697 
to the DNA-SMI-Gagp37B sequence and the respective T cell response 698 
rate (B) or the magnitude of responses (C) for single peptide-specific T 699 
cell responses as detected using the IFN- ELISPOT  and cryopreserved 700 
PBMC.  701 
702 
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Figures 703 
Figure 1 704 
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Figure 2 708 
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Figure 3 712 
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Figure 4 714 
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c 
 
 
d 
No. Peptide sequence HxB2 
position 
Frequency 
of 
recognition 
aa mismatch 
MVA vs DNA 
B/DNA BA [%] 
1 YVDRFYKTLRAEQAT 296-310 39.13% 6.67/13.33 
2 YKRWIILGLNKIVRMY 262-277 30.43% 0/0 
3 GATPQDLNMMLNIVGG 178-193 26.09% 12.5/6.25 
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4 IAGTTSTLQEQIGWMT 236-251 26.09% 6.25/6.25 
5 ILGLNKIVRMYSPVSI 267-282 26.09% 6.25/0 
6 WMTETLLVQNANPDCK 316-331 26.09% 0/6.25 
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Figure 5 716 
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